← Back to Search

Antioxidant

MitoQ for Sickle Cell Disease (MitoQ Trial)

N/A

Recruiting

Led By Ramasubramanian Kalpatthi, MD

Research Sponsored by University of Pittsburgh

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

18 years of age or older

Subjects

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline to 14 days

Awards & highlights

MitoQ Trial Summary

This trial will test if MitoQ is safe and effective in improving platelet function in patients with SCD.

Who is the study for?

This trial is for African American adults over 18 with sickle cell anemia. Healthy African American adults can also participate as controls. People cannot join if they are pregnant, have known high blood pressure, use anti-platelet medication, had a transfusion within the last month, require hemodialysis or treatment for obstructive sleep apnea.Check my eligibility

What is being tested?

The study is testing MitoQ, an antioxidant supplement not yet studied in sickle cell disease patients. It aims to see if MitoQ can improve how platelets function and reduce harmful oxygen-related molecules in those with sickle cell disease.See study design

What are the potential side effects?

Since this is a new test of MitoQ in sickle cell disease patients, specific side effects aren't fully known but may include typical reactions to supplements such as digestive discomfort or allergic reactions.

MitoQ Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I'm sorry, it seems that you have not completed the sentence. Could you please provide me with the complete criterion?

Select...

I have sickle cell anemia.

Select...

I am 18 years old or older.

MitoQ Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline to 14 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline to 14 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 14 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Effect of MitoQ on platelet activation markers in subjects with SCA

Secondary outcome measures

Hemolysis (disorder)

Effect of MitoQ on vascular dysfunction in subjects with SCA

Treatment related severe adverse events (SAE)

MitoQ Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Sickle cell patientsExperimental Treatment1 Intervention

Sickle Cell subjects administered oral MitoQ (20mg once a day for 14 days)

Group II: Non Sickle cell Control subjectsActive Control1 Intervention

Normal control subjects administered oral MitoQ (20mg once a day for 14 days)

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

MitoQ

2006

Completed Phase 2

~230

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of PittsburghLead Sponsor

1,722 Previous Clinical Trials

16,342,921 Total Patients Enrolled

Ramasubramanian Kalpatthi, MDPrincipal Investigator - University of Pittsburgh

University of Pittsburgh

Media Library

Sickle Cell Disease Clinical Trial 2023: MitoQ Highlights & Side Effects. Trial Name: NCT04109820 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any vacant slots for individuals to join this experiment?

"Affirmative. Clinicaltrials.gov reveals that this medical investigation, which was inaugurated on March 1st 2020, is recruiting participants as of now. Five sites need to enrol 15 individuals in total for the trial to be complete."

Answered by AI

How many participants are being sought for this clinical experiment?

"Affirmative. The clinical trial is actively recruiting participants, as indicated by the information provided on clinicaltrials.gov. This research project was initially posted on March 1st 2020 and has been recently revised on January 18th 2022 with a recruitment goal of 15 patients across 5 locations."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Effect of MitoQ on Platelet Function and Reactive Oxygen Species Generation in Patients With Sickle Cell Anemia

Ramasubramanian Kalpatthi 2020. "Effect of MitoQ on Platelet Function and Reactive Oxygen Species Generation in Patients With Sickle Cell Anemia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04109820.

All > Autoimmune Hemolytic Anemia > Sickle Cell Anemia